This whitepaper argues that contract manufacturing is not just a cost-saving tactic but can be a strategic differentiator for a biotech’s supply chain when done well.
What the piece covers
- Introduces ‘variabilization’ — converting fixed manufacturing costs into variable costs by outsourcing — as a way to free up capital and resources for product launches or other priorities
- Lists criteria for a strong CDMO partner: protecting intellectual property, meeting regulatory requirements, and providing responsive, cost-effective support
- Recommends starting a CDMO relationship with a lower-risk project to build confidence before scaling the partnership
Why Contract Manufacturing in Biotech?
Contract manufacturing in biotech is gaining a strategic role in the supply chains of some of the most successful companies. Global supply chains are often underutilized assets. By embracing the concept of variabilization– transforming fixed costs to variable costs, biotech companies can significantly leverage their supply chain, thereby freeing up valuable resources for new product launches or other priority initiatives. Key to this strategy is finding and engaging a knowledgeable and dependable contract manufacturer. Potential contract manufacturers must keep intellectual property (IP) safe, meet necessary regulatory requirements, and provide excellent cost effective client support. The first step in leveraging the supply chain is bringing together the contract manufacturer with operational and change-management leaders. By starting on a project where all parties are confident of success, a firm base is established for improving supply chain leverage.
Read this white paper to learn more about the benefits of contract manufacturing in biotech.
